Latest News ReVision Optics Announces First U.S. Commercial Cases of Raindrop Near Vision Inlay By Staff Monday, September 5, 2016 12:27 AM LAKE FOREST, Calif.—ReVision Optics announced the U.S. commercial launch of its Raindrop Near Vision Inlay. The initial launch plan calls for the company’s direct field force to focus on sites that participated in the U.S. IDE clinical trial, followed by a more broad-based expansion later in 2016.“We are excited to kick-off our U.S. launch with procedures performed by an outstanding group of ophthalmologists including Drs. Stephen Slade, Jeffery Whitman, Greg Parkhurst and Ralph Chu who treated patients on Aug. 30 in Houston and San Antonio, Texas, and in Bloomington, Minn.,” said John Kilcoyne, ReVision Optics president and CEO. “All of these surgeons are driving forces behind commercialization of the Raindrop Near Vision Inlay, having served as investigators in our clinical study.” The Raindrop Near Vision Inlay is a corneal inlay for the surgical correction of presbyopia. It has received approval by the U.S. Food and Drug Administration, authorization to affix the CE Mark for the European Union, license approval by the Ministry of Food and Drug Safety (South Korea), approval by the Therapeutic Goods Administration (Australia) and registration with the Medicines and Medical Safety Authority (New Zealand). Other country-specific registrations are pending.